Building on the reported clinical association between NPM1 mutations and atRA responsiveness [76], the effects of atRA and ATO on AML cell lines and primary AML samples with and without NPM1 mutations were investigated. This evidence concerns the gene NPM1 and acute myeloid leukemia.